Literature DB >> 16721844

Multicenter quality control of the detection of HIV-1 genome in semen before medically assisted procreation.

Christophe Pasquier1, Deborah Anderson, Corinne Andreutti-Zaugg, Rianne Baume-Berkenbosch, Florence Damond, Aviva Devaux, Yvon Englert, Julie Galimand, Carole Gilling-Smith, Odile Guist'hau, Lital Hollander, Marianne Leruez-Ville, Benoit Lesage, Anne Maillard, Anne-geneviève Marcelin, Marie-Paule Schmitt, Augusto Semprini, Maria Vourliotis, Chong Xu, Louis Bujan.   

Abstract

Couples in whom the man is HIV-1-positive may use medically assisted procreation in order to conceive a child without contaminating the female partner. But, before medically assisted procreation, the semen has to be processed to exclude HIV and tested for HIV nucleic acid before and after processing. The performance was evaluated of the technical protocols used to detect and quantify HIV-1 in 11 centers providing medically assisted procreation for couples with HIV-1 infected men by testing panels of seminal plasma and cells containing HIV-1 RNA and/or DNA. The performance of these tests varied due to the different assays used. False positive results were obtained in 14-19% of cases. The sensitivity for RNA detection in seminal plasma was 500-1,000 RNA copies/ml, over 500 RNA copies/10(6) cells in semen cells, and for DNA detection in semen cells 50-500 DNA copies/10(6) cells. The use of silica-based extraction seemed to increase the assay performance, whereas the use of internal controls to detect PCR inhibitor did not. This first quality control highlights the need for technical improvements of the assays to detect and quantify HIV in semen fractions and for regular evaluation of their performance. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721844     DOI: 10.1002/jmv.20636

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.

Authors:  Sidonie Lambert-Niclot; Gilles Peytavin; Claudine Duvivier; Catherine Poirot; Michèle Algarte-Genin; Sophie Pakianather; Jean-Luc Meynard; Marc-Antoine Valantin; Jean-Michel Molina; Philippe Flandre; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

2.  An optimized nested polymerase chain reaction (PCR) approach allows detection and characterization of human immunodeficiency virus type 1 (HIV-1) env and gag genes from clinical samples.

Authors:  Dayse Locateli; Patricia H Stoco; Carlos R Zanetti; Aguinaldo R Pinto; Edmundo C Grisard
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

3.  Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy.

Authors:  Christophe Pasquier; Karine Sauné; Stéphanie Raymond; Nathalie Moinard; Myriam Daudin; Louis Bujan; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2009-07-29       Impact factor: 5.948

4.  Timing of intermittent seminal HIV-1 RNA shedding in patients with undetectable plasma viral load under combination antiretroviral therapy.

Authors:  Xavier Ferraretto; Candice Estellat; Florence Damond; Pascale Longuet; Sylvie Epelboin; Pauline Demailly; Chadi Yazbeck; Marie-Astrid Llabador; Blandine Pasquet; Yazdan Yazdanpanah; Sophie Matheron; Catherine Patrat
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.